Logo image of ASRT

ASSERTIO HOLDINGS INC (ASRT) Stock Fundamental Analysis

NASDAQ:ASRT - Nasdaq - US04546C2052 - Common Stock - Currency: USD

0.6501  +0 (+0.08%)

Fundamental Rating

3

ASRT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. While ASRT seems to be doing ok healthwise, there are quite some concerns on its profitability. ASRT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ASRT had negative earnings in the past year.
ASRT had a positive operating cash flow in the past year.
In the past 5 years ASRT reported 4 times negative net income.
Of the past 5 years ASRT 4 years had a positive operating cash flow.
ASRT Yearly Net Income VS EBIT VS OCF VS FCFASRT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

1.2 Ratios

ASRT has a Return On Assets of -7.58%. This is in the better half of the industry: ASRT outperforms 70.71% of its industry peers.
ASRT has a better Return On Equity (-17.82%) than 71.72% of its industry peers.
Industry RankSector Rank
ROA -7.58%
ROE -17.82%
ROIC N/A
ROA(3y)-32.33%
ROA(5y)-21.33%
ROE(3y)-69.93%
ROE(5y)-52.34%
ROIC(3y)N/A
ROIC(5y)N/A
ASRT Yearly ROA, ROE, ROICASRT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

ASRT's Gross Margin of 68.61% is fine compared to the rest of the industry. ASRT outperforms 73.74% of its industry peers.
ASRT's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for ASRT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.36%
GM growth 5Y-6.47%
ASRT Yearly Profit, Operating, Gross MarginsASRT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

4

2. Health

2.1 Basic Checks

ASRT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ASRT has more shares outstanding
The number of shares outstanding for ASRT has been increased compared to 5 years ago.
Compared to 1 year ago, ASRT has a worse debt to assets ratio.
ASRT Yearly Shares OutstandingASRT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ASRT Yearly Total Debt VS Total AssetsASRT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

ASRT has an Altman-Z score of -2.49. This is a bad value and indicates that ASRT is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ASRT (-2.49) is comparable to the rest of the industry.
ASRT has a debt to FCF ratio of 1.47. This is a very positive value and a sign of high solvency as it would only need 1.47 years to pay back of all of its debts.
ASRT's Debt to FCF ratio of 1.47 is amongst the best of the industry. ASRT outperforms 94.44% of its industry peers.
ASRT has a Debt/Equity ratio of 0.32. This is a healthy value indicating a solid balance between debt and equity.
ASRT has a Debt to Equity ratio of 0.32. This is comparable to the rest of the industry: ASRT outperforms 43.43% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF 1.47
Altman-Z -2.49
ROIC/WACCN/A
WACC9.5%
ASRT Yearly LT Debt VS Equity VS FCFASRT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

ASRT has a Current Ratio of 1.77. This is a normal value and indicates that ASRT is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of ASRT (1.77) is worse than 63.13% of its industry peers.
ASRT has a Quick Ratio of 1.43. This is a normal value and indicates that ASRT is financially healthy and should not expect problems in meeting its short term obligations.
ASRT has a worse Quick ratio (1.43) than 64.65% of its industry peers.
Industry RankSector Rank
Current Ratio 1.77
Quick Ratio 1.43
ASRT Yearly Current Assets VS Current LiabilitesASRT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

ASRT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 77.23%, which is quite impressive.
Looking at the last year, ASRT shows a very negative growth in Revenue. The Revenue has decreased by -17.83% in the last year.
The Revenue for ASRT have been decreasing by -11.45% on average. This is quite bad
EPS 1Y (TTM)77.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.97%
Revenue 1Y (TTM)-17.83%
Revenue growth 3Y4.03%
Revenue growth 5Y-11.45%
Sales Q2Q%-2.43%

3.2 Future

ASRT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.26% yearly.
Based on estimates for the next years, ASRT will show a small growth in Revenue. The Revenue will grow by 4.16% on average per year.
EPS Next Y21.06%
EPS Next 2Y35.82%
EPS Next 3Y30.49%
EPS Next 5Y35.26%
Revenue Next Year-5.11%
Revenue Next 2Y2.72%
Revenue Next 3Y2.11%
Revenue Next 5Y4.16%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ASRT Yearly Revenue VS EstimatesASRT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M
ASRT Yearly EPS VS EstimatesASRT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ASRT. In the last year negative earnings were reported.
Also next year ASRT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ASRT Price Earnings VS Forward Price EarningsASRT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, ASRT is valued cheaper than 98.99% of the companies in the same industry.
Industry RankSector Rank
P/FCF 2.36
EV/EBITDA -6.88
ASRT Per share dataASRT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

ASRT's earnings are expected to grow with 30.49% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.82%
EPS Next 3Y30.49%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ASRT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASSERTIO HOLDINGS INC

NASDAQ:ASRT (5/1/2025, 6:50:10 PM)

0.6501

+0 (+0.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-12 2025-03-12/amc
Earnings (Next)05-12 2025-05-12/amc
Inst Owners29.96%
Inst Owner Change-0.04%
Ins Owners1.17%
Ins Owner Change4.58%
Market Cap62.26M
Analysts82
Price Target2.87 (341.47%)
Short Float %5.96%
Short Ratio14.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-54.52%
Min EPS beat(2)-145.1%
Max EPS beat(2)36.06%
EPS beat(4)1
Avg EPS beat(4)-48.75%
Min EPS beat(4)-145.1%
Max EPS beat(4)36.06%
EPS beat(8)1
Avg EPS beat(8)-494.59%
EPS beat(12)5
Avg EPS beat(12)-295.24%
EPS beat(16)7
Avg EPS beat(16)-216.06%
Revenue beat(2)1
Avg Revenue beat(2)4.61%
Min Revenue beat(2)-0.83%
Max Revenue beat(2)10.04%
Revenue beat(4)3
Avg Revenue beat(4)4.61%
Min Revenue beat(4)-0.83%
Max Revenue beat(4)10.04%
Revenue beat(8)5
Avg Revenue beat(8)-0.64%
Revenue beat(12)9
Avg Revenue beat(12)1.87%
Revenue beat(16)13
Avg Revenue beat(16)3.29%
PT rev (1m)-4.26%
PT rev (3m)-7.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-157.18%
EPS NY rev (1m)0%
EPS NY rev (3m)-154.29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.76%
Revenue NY rev (1m)-6.82%
Revenue NY rev (3m)-6.82%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.5
P/FCF 2.36
P/OCF 2.36
P/B 0.51
P/tB 1.53
EV/EBITDA -6.88
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)0.28
FCFY42.42%
OCF(TTM)0.28
OCFY42.42%
SpS1.3
BVpS1.26
TBVpS0.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.58%
ROE -17.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.61%
FCFM 21.13%
ROA(3y)-32.33%
ROA(5y)-21.33%
ROE(3y)-69.93%
ROE(5y)-52.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.36%
GM growth 5Y-6.47%
F-Score3
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF 1.47
Debt/EBITDA 5.51
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion 374.79%
Profit Quality N/A
Current Ratio 1.77
Quick Ratio 1.43
Altman-Z -2.49
F-Score3
WACC9.5%
ROIC/WACCN/A
Cap/Depr(3y)16.81%
Cap/Depr(5y)10.15%
Cap/Sales(3y)3.56%
Cap/Sales(5y)2.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.97%
EPS Next Y21.06%
EPS Next 2Y35.82%
EPS Next 3Y30.49%
EPS Next 5Y35.26%
Revenue 1Y (TTM)-17.83%
Revenue growth 3Y4.03%
Revenue growth 5Y-11.45%
Sales Q2Q%-2.43%
Revenue Next Year-5.11%
Revenue Next 2Y2.72%
Revenue Next 3Y2.11%
Revenue Next 5Y4.16%
EBIT growth 1Y-215.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year180.95%
EBIT Next 3Y63.98%
EBIT Next 5Y43.56%
FCF growth 1Y-45.61%
FCF growth 3Y69.74%
FCF growth 5Y-21.57%
OCF growth 1Y-46.76%
OCF growth 3Y68.7%
OCF growth 5Y-21.83%